Tracking-Surveillance in Medical Mammography Quality Auditing

Tracking, also called surveillance in some contexts, is the systematic process by which a mammography facility monitors every relevant event in a patient's pathway from the initial examination through recommended additional imaging, biopsy disposition, pathology correlation, and known subsequent cancer diagnoses. The destination of this process is not merely regulatory paperwork. It is a closed-loop feedback mechanism that measures interpretive accuracy, identifies gaps in care completion, and creates the operational conditions under which early-stage cancers are more likely to be found and acted upon before they progress.^1,2

Most facilities treat tracking as the minimum activity needed to satisfy an annual Mammography Quality Standards Act (MQSA) inspection. That view is incomplete. The regulatory floor requires facilities to follow the disposition of positive mammograms and to correlate those findings with biopsy results. The deeper mechanism is continuous outcome surveillance that reveals whether the facility's interpretations and its follow-up systems actually protect patients. Without that mechanism, performance metrics remain theoretical and lost-to-follow-up events remain invisible until a late-stage cancer appears.^1,2

Regulatory Foundation Under MQSA

The U.S. Food and Drug Administration (FDA) requires every certified mammography facility to establish and maintain a mammography medical outcomes audit program under 21 CFR 900.12(f). The purpose of the program is to ensure the reliability, clarity, and accuracy of mammogram interpretation. The facility must collect and review outcome data for all mammographic examinations performed. This includes follow-up on the disposition of all positive mammograms and correlation of pathology results with the interpreting physician's report.^1,2

A positive mammogram, for the core regulatory requirement, is one assessed as "Suspicious" or "Highly Suggestive of Malignancy." Facilities must also capture any cases of breast cancer among patients previously imaged at the facility that subsequently become known to the facility. In those cases the facility must promptly initiate follow-up on surgical or pathology results and review the prior mammograms. Analysis of the outcome data must be performed both individually for each interpreting physician and collectively for the facility as a whole.^1,2

The 2023 amendments to the MQSA implementing regulations, enforcement of which began on September 10, 2024, added three mandatory metrics that must appear in the annual audit:^2,3

• Positive predictive value: the percent of patients with positive mammograms who are diagnosed with breast cancer within one year of the examination date.
• Cancer detection rate: among patients initially examined with screening mammograms who receive an assessment of "Incomplete: Need additional imaging evaluation," "Suspicious," or "Highly Suggestive of Malignancy" on the screening examination or a subsequent diagnostic examination, the number of patients diagnosed with breast cancer within one year of the initial screening mammogram, expressed per 1,000 patients.
• Recall rate: the percentage of screening mammograms given an assessment of "Incomplete: Need additional imaging evaluation."

These calculations are required for each interpreting physician and for the facility aggregate. Facilities must designate an audit interpreting physician responsible for reviewing the results and notifying each interpreting physician of individual and collective performance. Audit data must be retained at least until the next annual MQSA inspection.²

The FDA leaves the design of the tracking system to the facility. The system may be manual or computerized, but it must include procedures to identify positive examinations, determine whether recommended biopsies occurred, obtain at least the benign-versus-malignant result, and feed that information back to the interpreting physicians. Inspectors examine the system itself, examples of biopsy results obtained, and documentation of attempts to obtain missing results.²

Expansion Beyond the Regulatory Floor: BI-RADS and Operational Tracking

The American College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS®) Atlas supplies the more complete framework that most high-performing facilities use. BI-RADS defines positive examinations more broadly for audit purposes. For screening, BI-RADS categories 0 and 3 (when used at screening) are treated as positive; categories 4 and 5 are positive for both screening and diagnostic examinations. The Atlas provides detailed guidance on data elements that should be collected (modality, number of examinations, recalls, short-interval follow-up recommendations, tissue diagnosis recommendations, pathology results, cancer staging) and on the derived statistics that allow meaningful comparison to national benchmarks.⁴

Those benchmarks, drawn from large consortia such as the Breast Cancer Surveillance Consortium, give facilities external reference points for cancer detection rate, abnormal interpretation rate, positive predictive values, sensitivity, specificity, and the proportion of detected cancers that are minimal or node-negative. Facilities that limit themselves to the three MQSA-required metrics can still pass inspection. Facilities that adopt the fuller BI-RADS audit gain the ability to detect underperformance early and to adjust technique, recall thresholds, or follow-up processes before patient harm accumulates.⁵

Operational tracking extends still further. It encompasses every recommended action that leaves the reading room: short-interval follow-up for BI-RADS 3 findings, diagnostic imaging after an incomplete screening assessment, biopsy scheduling, and return to routine screening after a benign work-up. Studies of real-world pathways demonstrate that incomplete follow-up after abnormal mammograms is common when systems are passive. A systematic review of primary-care follow-up after abnormal screening mammograms found failure-to-follow-up rates ranging from 7.2 percent to 33 percent within three months and from 27.3 percent to 71.6 percent at six months, with higher rates among ethnic-minority women and those with lower educational attainment.⁶

Closed-loop tracking systems that combine electronic registries with active outreach reduce these failures substantially. In an analogous program for incidental pulmonary nodules, an automated tracking registry lowered the rate of tracking failure from 74 percent to 10 percent. Breast-imaging programs that embed navigators or automated overdue-reminder workflows report measurable gains in completion of diagnostic evaluation and shorter intervals from abnormal screening to definitive diagnosis.⁷

Patient-Level Consequences and Operational Implications

The patient consequence of incomplete tracking is delayed or missed diagnosis. Interval cancers diagnosed after a negative mammogram already carry a higher likelihood of poor prognosis than screen-detected cancers. Data from the PROSPR consortium demonstrate that cancers diagnosed after negative screening mammography are more likely to have a poor prognosis (43.8 percent) than those detected after positive mammography (26.9 percent). When a positive or incomplete assessment is never resolved, that risk is compounded by system failure rather than by biology alone. Facilities that systematically close every recommended loop convert interpretive accuracy into actual stage shift at the population level.⁸

Operationally, the distinction between minimum regulatory tracking and robust surveillance is the difference between a system that survives inspection and a system that improves outcomes. The former can be satisfied with a spreadsheet of BI-RADS 4 and 5 cases and a handful of pathology reports. The latter requires continuous capture of all actionable recommendations, automated identification of overdue patients, documented outreach attempts, and regular review of both medical and process metrics by clinical leadership. Counterarguments that full tracking is resource-intensive are acknowledged; the counter-evidence is that the cost of delayed diagnosis, both clinical and medicolegal, exceeds the cost of a functional closed-loop process.

Leadership therefore faces a concrete question: Is the facility's tracking system engineered solely to produce the three numbers required by the inspector, or is it engineered to ensure that every patient who leaves with an actionable recommendation actually completes the next step in the pathway?

---

About the Author

Richard D. Lippert Jr. is the founder of Mammologix and has supported breast imaging centers with patient follow-up tracking, audit preparation, compliance documentation, and operational strategy since 1995.

References

1. U.S. Food and Drug Administration. 21 CFR 900.12(f) Quality assurance -- mammography medical outcomes audit. eCFR. ecfr.gov/current/title-21/section-900.12

2. U.S. Food and Drug Administration. Mammography Quality Standards Act and Regulation Amendments: Small Entity Compliance Guide. August 2024. fda.gov/media/181152/download

3. U.S. Food and Drug Administration. Important Information: Final Rule to Amend the Mammography Quality Standards Act (MQSA). fda.gov/radiation-emitting-products/mqsa-final-rule

4. American College of Radiology. BI-RADS Atlas: Follow-up and Outcome Monitoring (Basic Audit guidance). acr.org/FUOM-Basic-Audit (PDF)

5. Lehman CD, Arao RF, Sprague BL, et al. National performance benchmarks for modern diagnostic digital mammography: update from the Breast Cancer Surveillance Consortium. Radiology. 2017;283(1):49-58. pmc.ncbi.nlm.nih.gov/PMC5375630

6. Reece JC, et al. Delayed or failure to follow-up abnormal breast cancer screening mammograms in primary care: a systematic review. BMC Cancer. 2021;21:373. pmc.ncbi.nlm.nih.gov/PMC8028768

7. Shelver J, et al. Effect of an automated tracking registry on the rate of tracking failure for incidental pulmonary nodules. J Am Coll Radiol. 2017;14(8):1030-1037. Abstract

8. Sprague BL, et al. Breast cancer with a poor prognosis diagnosed after screening mammography with negative results. JAMA Oncol. 2018;4(7):998-1001. pmc.ncbi.nlm.nih.gov/PMC6145719